Statins

HMG-CoA Reductase Inhibitors (Atorvastatin, Rosuvastatin, Simvastatin, et al.)

Statins are the world's most-prescribed drug class — taken by more than 35 million Americans daily. They block HMG-CoA reductase, the liver's rate-limiting enzyme for cholesterol synthesis, cutting LDL by 30–55%. Their cardiovascular evidence base is unmatched: 300,000+ patient-years across landmark trials, with a consistent 20–35% reduction in major cardiac events per unit of LDL lowering. The science is moving fast. A 2026 Oxford meta-analysis of 23 trials has definitively debunked most feared side effects as nocebo, new real-world data links statins to lower Alzheimer's risk, and emerging cancer research is opening a new chapter. The foundational classic of modern medicine may be far from finished.

Last updated
2026-05-09

How to read this sphere

The percentage on each node is the confidence level that a particular benefit or side effect is actually real — higher means more high-quality studies back it up. Once confidence crosses ~80%, the effect is considered Pacified: generally accepted as true by the scientific community.

Position reflects confidence: nodes closer to the center have stronger evidence; nodes near the edge are still speculative. As more studies are published, nodes migrate inward — or disappear entirely if the evidence collapses.

Statins are among the most-studied drugs in history, so the Core is dense and tight. What's interesting right now is the outer edge: a 2026 Oxford meta-analysis debunked most feared side effects as nocebo, while new data signals Alzheimer's protection and cancer risk reduction. Old drug, new chapter.

9
Benefits
6
Malefices
20
Sources
78%
Avg. Confidence
BENEFITSMALEFICESCore80–100%Inner Mantle60–80%Outer Mantle40–60%Crust10–40%Cancer Risk Redu… (C.L. 45%)Alzheimer's & De… (C.L. 52%)Earlier, Lower L… (C.L. 65%)Plaque Stabiliza… (C.L. 70%)Primary CVD Prev… (C.L. 78%)Stroke Prevention (C.L. 90%)All-Cause Mortal… (C.L. 93%)CVD Event Reduct… (C.L. 97%)LDL Cholesterol … (C.L. 99%)Liver Enzyme Ele… (C.L. 55%)Feared Side Effe… (C.L. 80%)Drug Interaction… (C.L. 82%)Rhabdomyolysis (C.L. 85%)New-Onset Diabet… (C.L. 90%)Muscle Pain (SAMS) (C.L. 92%)

All Sources

Phase III RCT6 sources
Meta-Analysis9 sources
Observational Study5 sources

Last updated: 2026-05-09 · Data compiled from PubMed, ClinicalTrials.gov, FDA, and EMA databases.